Table 1.
Patients' clinical characteristics according to smoking history
| Characteristics | Total (n=71) (%) | Never-/former light smokers (n=30) (%) | Current smokers (n=41) (%) | P -value |
|---|---|---|---|---|
| Median age (range), years | 60 (29-78) | 58.5 (35-76) | 60 (29-78) | 0.228 |
| Age, years | ||||
| < 60 | 33 (46.5) | 16 (53.5) | 17 (41.5) | 0.322 |
| ≥ 60 | 38 (53.5) | 14 (46.7) | 24 (58.5) | |
| Gender | ||||
| Male | 45 (63.4) | 6 (20.0) | 39 (95.1) | < 0.001 |
| Female | 26 (36.6) | 24 (80.0) | 2 (4.9) | |
| Performance status | ||||
| 0-1 | 63 (88.7) | 26 (86.7) | 37 (90.2) | 0.714 |
| 2 | 8 (11.3) | 4 (13.3) | 4 (9.8) | |
| Histology | ||||
| Adenocarcinoma | 65 (91.5) | 27 (90.0) | 38 (92.7) | 0.795 |
| Large cell carcinoma | 1 (1.4) | 0 (0.00) | 1 (2.4) | |
| Not otherwise specified, NOS | 5 (7.0) | 3 (10.0) | 2 (4.9) | |
| Extent of metastasis | ||||
| M1a | 25 (35.2) | 10 (33.3) | 15 (36.6) | 0.777 |
| M1b | 46 (64.8) | 20 (66.7) | 26 (63.4) | |
| First-line chemotherapy regimens | ||||
| Pemetrexed-cisplatin | 57 (80.3) | 23 (76.7) | 34 (82.9) | 0.513 |
| Pemetrexed-carboplatin | 14 (19.7) | 7 (23.3) | 7 (17.1) | |
| Cycles of first-line chemotherapy | ||||
| four | 52 (73.2) | 23 (76.7) | 29 (70.7) | 0.577 |
| five-six | 19 (26.8) | 7 (23.3) | 12 (29.3) | |
| Response of first-line chemotherapy | ||||
| Partial reponse (PR) | 38 (53.5) | 20 (66.7) | 18 (43.9) | 0.057 |
| Stable disease (SD) | 33 (46.5) | 10 (33.3) | 23 (56.1) | |
| Second-line treatment | ||||
| Yes | 53 (74.6) | 24 (80.0) | 29 (70.7) | 0.375 |
| No | 18 (25.4) | 6 (20.0) | 12 (29.3) |